Search Results
Jun 01, 2026, 13:37 ET Rendimento Bank Expands International Reach with Exclusive Account for Non-Resident Brazilians and Foreigners
products through close and personalized service to its clients. The companies Rendimento Bank, Rendimento Câmbio DTVM, Rendimento Pay and Rendimento SCD are a part of Rendimento's conglomerate. Operating under the motto "your financial partner that makes it happen," the institution has extensive expertise
More news about: Rendimento
Jun 01, 2026, 13:37 ET Rendimento Bank Expands International Reach with Exclusive Account for Non-Resident Brazilians and Foreigners
products through close and personalized service to its clients. The companies Rendimento Bank, Rendimento Câmbio DTVM, Rendimento Pay and Rendimento SCD are a part of Rendimento's conglomerate. Operating under the motto "your financial partner that makes it happen," the institution has extensive expertise
More news about: Rendimento
May 27, 2026, 09:31 ET Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
dozen drug product launches. Dr. Brown serves on the alumni board of Temple University's College of Science and Technology and is Co-Managing Partner of SCD Ventures."Sensorium has built a disciplined clinical development organization around a discovery platform designed to generate differentiated
More news about: Sensorium Therapeutics
May 14, 2026, 07:30 ET Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Aramchol down-regulates stearoyl CoA desaturase 1 (SCD1) in hepatocytes and in hepatic stellate cells (HSC's) and other tissues including various cancers. Metabolic-dysfunction associated steatohepatitis
More news about: Galmed Pharmaceuticals Ltd.
May 06, 2026, 07:30 ET Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
and impaired regenerative remodeling. SCD1, a key enzyme controlling monounsaturated fatty-acid synthesis and membrane-lipid composition, sits at the center of this biology. Studies have shown SCD1 upregulation in experimental heart failure and linked cardiac SCD activity to lipid overload, collagen gene
More news about: Galmed Pharmaceuticals Ltd.
May 05, 2026, 08:00 ET Spring Aging Wellness Expo Returns to South Point Hotel and Casino
Beecher, licensed marriage and family therapist."Biomarkers and the Early Detection of Alzheimer's Disease" — Jeffrey Cummings, MD, ScD, physician and research professor, UNLV Center for Brain Health."Remembering with Love: Grief, Connection, and Celebrating Life" —
More news about: Las Vegas Review-Journal
Apr 21, 2026, 08:20 ET SHAPING THE FOOD SYSTEM OF 2035
Among the featured presenters on this year's program are Teresa Fung, ScD, RD, Ruby Winslow Linn professor of nutrition at Simmons University and adjunct professor of nutrition at Harvard T.H. Chan School of Public Health;
More news about: The Culinary Institute of America
Apr 16, 2026, 14:22 ET APhA Foundation introduces 2026-2027 Board of Directors
President:John D. Grabenstein, RPh, PhD, ScD (Hon)Vice President:
More news about: American Pharmacists Association Foundation
Apr 14, 2026, 07:30 ET Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
metastatic colonization in the lipid-rich brain microenvironment. SCD1, an enzyme that converts saturated fatty acids into monounsaturated fatty acids, is essential for lipid synthesis and membrane production in proliferating cancer cells. Owing to SCD1 upregulation in p53-deficient tumors, its downregulation
More news about: Galmed Pharmaceuticals Ltd.
Apr 09, 2026, 07:30 ET Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
stearoyl-CoA desaturase 1 (SCD1) as a potential target for treatment of synucleinopathies.Based on the evidence for the role of SCD1 inhibition in mitigating synucleinopathies, Galmed's breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor position Aramchol
More news about: Galmed Pharmaceuticals Ltd.
Mar 31, 2026, 09:00 ET NEW CAMPAIGN "BEAT CANCER OFF" WANTS MEN TO MASTURBATE 21 OR MORE TIMES A MONTH
prompt), out of home, social, and brand partnerships.The campaign is also supported by leading prostate cancer specialist Dr. Lorelei Mucci, ScD, Professor of Epidemiology and Director of the Cancer Epidemiology and Cancer Prevention Program at the Harvard T.H. Chan School of Public Health, and
More news about: FCancer
Mar 31, 2026, 08:00 ET Safi Biotherapeutics Inc. and DesiCorp Inc. Initiate Collaboration to Support Freeze-Drying of mRBCs
the most advanced in the industry, and the company's readily addressable markets include chronic transfusion indications, such as sickle-cell disease (SCD), and acute transfusion settings, such as civilian and military hospitals during critical times of need. Safi leadership, comprised of industry and cell
More news about: Safi Biotherapeutics
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in December.A second SCD study, sponsored by St. Jude Children's Research Hospital, continues to enroll
More news about: BioLineRx Ltd.
Mar 19, 2026, 12:15 ET ASHP Names Samuel Calabrese as Executive Vice President and CEO
president and CEO, effective May 1, 2026. Calabrese will become ASHP's fifth CEO in its 84-year history, succeeding longtime CEO Paul W. Abramowitz, PharmD, ScD (Hon), FASHP, who retired
More news about: ASHP (American Society of Health-System Pharmacists)
Feb 26, 2026, 08:00 ET Orsini Now Distributing Gene Therapies LYFGENIA™, ZYNTEGLO™, SKYSONA™
first-in-class FDA-approved ex vivo gene addition therapy indicated for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events. Read the full Prescribing Information
More news about: Orsini
Feb 17, 2026, 08:35 ET The American Diabetes Association Announces 2026 Pathway to Stop Diabetes Grant Recipients
year, Pathway grants have been awarded to the following researchers and their breakthrough projects:Christina Astley, MD, ScD, Assistant Professor of Pediatrics, Harvard Medical School, and Assistant in Pediatrics, Boston Children's HospitalDr. Astley's research,
More news about: American Diabetes Association
Jan 13, 2026, 09:00 ET Recast and System Center Dudes Showcase Free Tools for Intune from Microsoft MVPs
Microsoft Enterprise Mobility suite, including Configuration Manager, Intune, Autopilot, Entra ID, Defender, and more. In addition to consulting, SCD offers the SCD Reporting Suite, Power BI dashboards, and step-by-step installation and configuration guides that help organizations manage and secure their
More news about: Recast Software
Jan 08, 2026, 08:00 ET Safi Biotherapeutics and ARMI | BioFabUSA Complete Successful Technical Transfer of Initial Clinical Scale 10L mRBC Production System
the most advanced in the industry, and the company's readily addressable markets include chronic transfusion indications such as sickle-cell disease (SCD) and acute transfusion settings such as civilian and military hospitals during critical times of need. Safi leadership, comprised of industry and cell
More news about: Safi Biotherapeutics
Jan 06, 2026, 07:19 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis
patients continued their initial treatment with ruxolitinib. CK0804 responders demonstrated decreased circulating levels of TGFβ1, TGFβ2, FGF, PDGF, and sCD40L, reduced plasma and bone marrow monocytes, and normalization of the bone marrow myeloid‑to‑erythroid ratio.About CK0804CK0804
More news about: Cellenkos, Inc.
Jan 02, 2026, 13:29 ET Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
sickle cell disease or transfusion-dependent beta thalassemia at the American Society of Hematology Annual Meeting. In the Phase 3 CLIMB-151 study for SCD, all four patients with sufficient follow-up achieved freedom from vaso-occlusive crises for at least 12 consecutive months, with the longest VOC-free
More news about: Equity Insider
Dec 10, 2025, 10:00 ET APhA names Thomas E. Menighan as the 2026 Remington Honor Medal recipient
Dec. 10, 2025 /PRNewswire/ -- The American Pharmacists Association (APhA) is proud to announce that Thomas E. Menighan, BSPharm, MBA, ScD, has been selected as the
More news about: American Pharmacists Association
Dec 10, 2025, 08:52 ET Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia
in total symptom burden was observed in 78% of patients (9 of 11).Biomarker profile: Clinical responses correlated with reductions in FGF, sCD40L, PDGF‑AA, and PDGF‑AA/BB.Thrombocytopenic subgroup: All three thrombocytopenic patients tolerated the intensive CK0804 regimen; all had a 100%
More news about: Cellenkos, Inc.
Dec 09, 2025, 15:04 ET Health Systems Embrace New Strategies to Navigate Disruptions
to their organizations as we prepare for disruptions that will define the healthcare system of the future," said ASHP CEO Paul W. Abramowitz, PharmD, ScD (Hon), FASHP. "This year's Pharmacy Forecast helps translate emerging opportunities into actionable strategies to safeguard patients, stabilize
More news about: ASHP (American Society of Health-System Pharmacists)
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Therapeutics. "BEAM-101, designed to be a one-time, disease-modifying therapy, has the potential to meaningfully improve outcomes for people with severe SCD."The therapy mimics naturally occurring protective variants through precise base editing of hematopoietic stem cells, representing Beam's
More news about: Equity Insider
Dec 08, 2025, 08:30 ET Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
cells. SCD1 inhibition augments regorafenib (Stivarga®) activity through ATM-AMPK-autophagy signaling. These findings provide the scientific and translational rationale for the initiation of a Phase 1/2 clinical trial of the combination of standard of care regorafenib with the SCD1 inhibitor
More news about: Galmed Pharmaceuticals Ltd.